title: Is it possible to optimize the use of targeted therapies in the treatment of renal cell carcinoma?
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Procopio
authors.forename: Elena
authors.initials: E
authors.lastname: Verzoni
authors.forename: Valentina
authors.initials: V
authors.lastname: Guadalupi
authors.forename: Roberto
authors.initials: R
authors.lastname: Iacovelli
authors.forename: Emilio
authors.initials: E
authors.lastname: Bajetta
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D000068338:Everolimus; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D058990:Molecular Targeted Therapy / Q000379:methods*; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D020123:Sirolimus / Q000031:analogs & derivatives / Q000627:therapeutic use; D000077157:Sorafenib
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000068338:Everolimus; D000077157:Sorafenib; D020123:Sirolimus